Lundbeck
HLUN-B.CO
#2596
Rank
A$9.97 B
Marketcap
A$10.51
Share price
0.63%
Change (1 day)
11.13%
Change (1 year)
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.

P/E ratio for Lundbeck (HLUN-B.CO)

P/E ratio as of December 2025 (TTM): 11.4

According to Lundbeck's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 11.4016. At the end of 2024 the company had a P/E ratio of 12.7.

P/E ratio history for Lundbeck from 2022 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202412.7-6.11%
202313.57.05%
202212.6

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.